INmune Bio (NASDAQ:INMB) Posts Quarterly Earnings Results, Beats Estimates By $0.04 EPS

INmune Bio (NASDAQ:INMB) posted its earnings results on Thursday. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04, FiscalAI reports.

Here are the key takeaways from INmune Bio’s conference call:

• CORDStrom is moving toward regulatory filing — the company completed a rapid-assessed PIP, started process?validation manufacturing runs, signed a supply agreement with Anthony Nolan for umbilical cords, and expects to submit the U.K. MAA in early Q3 as it aims for commercial manufacture in 2027.
• XPro development continues with additional MINDFuL imaging analyses (MRI myelin preservation and structural integrity) and the company is exploring rare?disease trials and partner options to define late?stage/regulatory paths.
• Operational spending fell this quarter, with net loss narrowing to approximately $5.4 million (from $9.7M) and R&D down to ~$3.6M (from $7.6M), reflecting lower burn compared with the prior year period.
• Cash and equivalents were approximately $21.4 million at March 31, 2026, which management says funds operations only through Q1 2027, indicating a near?term need for additional financing or partnerships to support commercialization and late?stage programs.

INmune Bio Trading Down 5.9%

NASDAQ:INMB traded down $0.09 on Thursday, reaching $1.43. The stock had a trading volume of 311,985 shares, compared to its average volume of 244,408. The company has a 50-day moving average of $1.31 and a 200 day moving average of $1.53. The stock has a market cap of $38.01 million, a P/E ratio of -0.75 and a beta of 1.04. INmune Bio has a 12-month low of $1.09 and a 12-month high of $11.64.

Hedge Funds Weigh In On INmune Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in INmune Bio in the 4th quarter valued at about $32,000. XTX Topco Ltd raised its stake in shares of INmune Bio by 41.3% in the 4th quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock valued at $107,000 after purchasing an additional 20,121 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of INmune Bio in the 4th quarter valued at about $26,000. Jain Global LLC acquired a new stake in shares of INmune Bio in the 4th quarter valued at about $66,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of INmune Bio by 20.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after purchasing an additional 8,427 shares in the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

INMB has been the topic of a number of recent analyst reports. Lucid Cap Mkts upgraded shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 11th. Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.00.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.